Sentences with phrase «cell cancer after»

Stein MN, Hirshfield KM, Zhong H, Singer EA, Ali SM, Ganesan S. Response to crizotinib in a patient with MET - mutant papillary renal cell cancer after progression on tivantinib.

Not exact matches

In clinical trials the treatment — which involves extracting individual patients» immune T - cells, modifying them to seek out tell - tale biological markers associated with blood cancers like aggressive lymphoma, and then pumping those modified killer cells back into the body — has shown major promise, in some cases eliminating all signs of the cancer in patients six months after treatment.

BMS's drug, ipilimumab (Yervoy), was the first checkpoint inhibitor (a kind of cancer immunotherapy drug that essentially helps the immune system release its brake and go after tumor cells it might normally miss) to get approved in the US in 2011 for melanoma.

It's the second approval for this pioneering approach to cancer treatment, which involves re-engineering patients» own immune cells to become cancer killers, after the FDA's approval of Novartis» Kymriah in August.

Adoptive cell therapy for hard - to - treat blood cancers, after all, are widely expected to be the standard of care within a decade, and it should therefore grow to become one of the most lucrative markets in all of biotech.

After her encounter in the garden with what she calls elsewhere a «slow - moving sinister aggregation of cells... like a cancer looking for a host,» wherever she goes and whatever she does, what she has seen accompanies her: «a body inside my body... budding and malign.»

Philippa Taylor explained why she thought it was an encouraging discovery: «There could be real benefits for some people, particularly young girls or people who are going through cancer treatment or chemotherapy and that destroys any chance of having their own eggs and growing eggs cells so if you can remove ovarian tissue, grow some egg cells outside the womb and implant them after the treatment then that could be very positive.»

It offers cardio protection, it helps lower bad cholesterol, it may help prevent the progression of multiple sclerosis, it has the ability to regenerate brain cells after a stroke, it has the ability to cross the blood - brain barrier to potentially ward off Alzheimer's disease, apparently it's good at wiping amyloid plaque from the brain (which studies haves linked to Alzheimer's), it may help to prevent certain types of cancer, and studies have shown that it inhibits cancer cell growth and metastases (meaning it keeps cancer from spreading).

When EGCg inhibits tNOX, cancer cells can still divide, but can not grow after dividing, so they die.

Apparently cancer stem cells are the reason cancer often recurs even after chemotherapy and remission.

Seeing a cell of life developing within my body after having seen abnormal cancer cells restored my faith in many ways.

After being a nurse in the PICU, I thought about all of the genetic disorders my patients had encountered, (i.e. various cancers, cystic fibrosis, muscular dystrophy) and I wondered if there were anyway stem cells could have cured or at least improved their conditions.

It is possible that stimulating these cells artificially after menopause, when natural estrogen levels drop, could contribute to breast cancer.

After all, what is cancer but a group of cells in dis - alignment with the body and we think nothing of eradicating them to preserve the health and sanctity of the body.

She carried in her cells a dangerous genetic mutation and died when she was 28, after refusing surgery for her aggressive, inherited breast cancer.

Worse, after a biopsy, specialists spotted an even more disconcerting complication lurking at the edge of the pathology specimen: stray cancer cells.

In the hippocampus, a brain region vital for laying down new memories, «stem cells continue to add new circuit elements,» says Stanford University neuroscientist Theo D. Palmer, who helped Monje find out why brain fogginess can persist for years after cancer treatment has ended.

TO KILL a tumour, go after its neighbours: it seems to be the tumour - free tissue surrounding colon tumours that fosters the cancer's most pernicious cells.

Previous work in Weinberg's lab had shown that after a tumor forms in one part of the body, some of the cancer cells undergo EMT, Mani explains.

A new study has identified a group of molecules in prostate - cancer cells that doctors might one day use to distinguish which patients should be treated with radiation therapy if rising PSA levels indicate their cancer has recurred after surgical removal of the prostate.

Approximately one year after successful treatment with cytotoxic chemotherapy and radiotherapy, patients with advanced Small Cell Lung Cancer (SCLC), which primarily affects heavy smokers, generally relapse with recurrence of tumours that are resistant to further chemotherapy.

The removal of these components might be expected to unleash an assault by the immune system on cancer cells left after surgery.

The findings inject hard facts into a debate that has long divided the medical community, with many radiation oncologists preferring adjuvant therapy — radiation given soon after prostate removal to kill off any remaining cancer cells — and many urologists preferring salvage therapy — radiation given later, when prostate - specific antigen tests suggest it's needed.

Soon after lung cancer cells (in green) spread into the brain, extracellular matrix molecules (in red) can shield them from the hostile surroundings.

Patients with metastatic non-small cell lung cancer will always progress after chemotherapy, so most patients go on to be treated with immunotherapy, a type of therapy that uses the body's immune system to fight cancer.

By hitting breast cancer cells with a targeted therapeutic immediately after chemotherapy, researchers from Brigham and Women's Hospital (BWH) were able to target cancer cells during a transitional stage when they were most vulnerable, killing cells and shrinking tumors in the lab and in pre-clinical models.

By hitting breast cancer cells with a targeted therapeutic immediately after chemotherapy, researchers were able to target cancer cells during a transitional stage when they were most vulnerable.

Previous trials of retinoids against breast cancer have been conducted only after anti-estrogen treatments, at which point, «we were already getting expansion of cancer stem cells — treating with a retinoid after that was already too late,» Fettig says.

She was on her way out to a pub after a scientific conference when she spotted Paul Nurse, who was working on cell - cycle regulation at Imperial Cancer Research Fund in London.

Researchers at Dana - Farber / Boston Children's Cancer and Blood Disorders Center report promising outcomes from a clinical trial with patients with a rare form of bone marrow failure who received a hematopoietic stem cell transplant (HSCT) after pre-treatment with immunosuppressive drugs only.

After the modified T cells make many copies of themselves in the lab, they're unleashed in the patient's bloodstream to find and kill cancer cells.

During lab testing, the compound «markedly inhibited» the growth of three human pancreatic cancer cell lines five days after treatment and induced the death of pancreatic cancer cells.

Dr Lee Campbell, Research Projects and Science Communications Manager at Cancer Research Wales, who part - fund the study, commented: «This is an exciting breakthrough as cancer stem cells are thought to be responsible for the failure of many cancer treatments and the re-emergence of cancers, often many years after the initial diCancer Research Wales, who part - fund the study, commented: «This is an exciting breakthrough as cancer stem cells are thought to be responsible for the failure of many cancer treatments and the re-emergence of cancers, often many years after the initial dicancer stem cells are thought to be responsible for the failure of many cancer treatments and the re-emergence of cancers, often many years after the initial dicancer treatments and the re-emergence of cancers, often many years after the initial disease.

The researchers hope that ultimately human trials will prove the efficacy of the OH14 compound in sensitising tumour cells and cancer stem cells to existing drug - based therapies thus disabling tumours from seeding new growth after treatment.

These cancer stem cells act like the seeds of cancer and are responsible for re-growing a tumor after therapy.

With these in vitro test methods, the KU researchers have shown that anti-CD44s antibody can reduce pancreatic cancer cell growth, metastasis and ability of the tumors to recur after radiation therapy.

Being overweight or obese has been known to increase the risk of multiple myeloma, a cancer of the plasma cells in the blood and bone marrow that develops more often after age 60.

«In order to block tumor recurrence after radiation therapy, we used an antibody to target and inhibit these cancer stem cells,» said Dr. Xu.

In some cases, a minority of cells called TICs, or cancer stem cells, are culpable of repopulating the tumor after therapy.

Until recently, Ain was renowned for a highly prized repository of 18 immortal cancer cell lines, which he developed by harvesting tissue from his patients» tumors after removal, carefully culturing them to everlasting life in vials.

Liang Xu, Ph.D. member of the KU Cancer Center's Drug Discovery, Delivery and Experimental Therapeutics program and associate professor of molecular biosciences at KU, has discovered that targeting a cell - surface receptor called «CD44s» can block pancreatic tumor formation and recurrence after radiotherapy.

They then induced the two groups of mice to become asthmatic, after which the mice were challenged with breast cancer cells.

PARP inhibitors prevent cancer cells from repairing themselves after experiencing DNA damage (for example from chemotherapy or radiation).

After treatment with AZA, the epigenetic changes were reversed, rendering the cancer cells unable to evade the immune system any longer.

Without an infection, the few mutated cells that could potentially cause cancer stop proliferating after several divisions.

Phase I / II clinical trial results reported at the American Society for Clinical Oncology (ASCO) Annual Meeting 2015 show promising results for investigational drug brigatinib against ALK + non-small cell lung cancer (NSCLC), with 58 of 78 ALK + patients responding to treatment, including 50 of 70 patients who had progressed after previous treatment with crizotinib, the first licensed ALK inhibitor.

To make the vaccine, cancer cells are harvested from a tumor after surgery and stripped of their proteins; then those proteins are cultured with dendritic cells, a subclass of white blood cells, drawn from the patient's blood.

Loss of either GSTO1 or RYR1, the researchers report, decreased the number of cancer stem cells in the primary tumor, blocked metastasis of cancer cells from the primary tumor to the lungs, decreased the duration of chemotherapy required to induce remission and increased the duration of time after chemotherapy was stopped that the mice remained tumor - free.

After a median follow - up of 11 months, 11 of the 13 patients who responded remain on the study, including one patient who had non-small cell lung cancer (NSCLC) with a ROS1 gene fusion who has had a complete response that has been maintained for more than two years.

This image shows autophagic vesicles containing mutant K - Ras formed in the membrane of human pancreatic cancer cells after exposure to neratinib.